Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Lanadelumab (SHP643) in Japanese Subjects With Hereditary Angioedema

NCT04180163 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT04180163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04180163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Lanadelumab (SHP643) in Japanese Subjects With Hereditary Angioedema
Lead sponsor
Shire
Phase
Phase 3
Overall status
Completed
Start date
December 12, 2019
Completion date
August 26, 2021
Enrollment
12 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema (hae)